Chinese firm gets approval to begin human testing for potential coronavirus vaccine

[June 23, 2020]  BEIJING (Reuters) - China has approved a coronavirus vaccine candidate developed by Chongqing Zhifei Biological Products' unit to begin human testing, the company said in a filing on Tuesday.

The potential vaccine, co-developed by Anhui Zhifei Longcom Biopharmaceutical and the Institute of Microbiology of the Chinese Academy of Sciences, has received a certificate from the National Medical Products Administration to launch clinical trials.

Chinese researchers and companies are testing six experimental shots in humans, and more than a dozen vaccines are in different stages of clinical trials globally against the virus that has killed over 470,000 people.

However, none of the them have passed large-scale, late-stage phase 3 clinical trials, a necessary step before entering the consumer market.

(Reporting by Colin Qian, Roxanne Liu and Se Young Lee in Beijing; Editing by Muralikumar Anantharaman)

[© 2020 Thomson Reuters. All rights reserved.]

Copyright 2020 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.